Vaccines, coming of age after 200 years

FEMS Microbiology Reviews

Volumn 24, Issue 1, 2000, Pages 9-20

  Mäkelä, P Helena ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Adjuvant; Conjugate vaccine; DNA vaccination; Genomic; Immune response profile; Live vaccine; Mucosal immunization; Vaccine

Indexed keywords

DNA VACCINE; LIVE VACCINE; VACCINE;

HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; MEDICAL RESEARCH; REVIEW; VACCINATION;

CANCER VACCINES; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; IMMUNIZATION SCHEDULE; VACCINATION; VACCINES; VACCINES, ATTENUATED; VACCINES, CONJUGATE; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 0038464777     PISSN: 01686445     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-6445(99)00025-X     Document Type: Review

References (78)

1. Jenner, E. (1798) An Inquiry into the Causes and Effects of the Variolae Vaccine. Low, London.
2. Pasteur L. De l'attenuation du virus du cholera des poules. C.R. Acad. Sci. Paris. 91:1880;673-680.
3. Pasteur L., Chamberland C.-E., Roux R. Sur la vaccination charbonneuse. C.R. Adac. Sci. Paris. 92:1881;1378-1383.
4. Pasteur L. Methode pour prevenir la rage apres morsure. C.R. Acad. Sci. Paris. 101:1885;765-772.
5. Salmon D.E., Smith T. On a new method of producing immunity from contagious diseases. Am. Vet. Rev. 10:1886;63-69.
6. Kolle W. Zur aktiven immunizierung der menschen gegen cholera. Cent.bl. Bakteriol. I. Abt. Jena. 19:1896;97-104.
7. Haffkine W.M. Remarks on the plague prophylactic fluid. Br. Med. J. 1:1897;1461.
8. World Health Organization (1980) The Global Eradication of Smallpox. Final report of the global commission for the certification of smallpox eradication. Public Health No. 4, WHO, Geneva.
9. Fenner, F., Henderson, D.A., Arita, I. et al. (1988) Smallpox and its Eradication. WHO, Geneva.
10. Wright P.F., Kim-Farley R.J., de Quadros C.A., et al. Strategies for the global eradication of poliomyelitis by the year 2000. N. Engl. J. Med. 325:1991;1774.
11. Cochi, S.L., Hull, H.F., Suter, R.W. et al. (1997) Global poliomyelitis eradication initiative: status report. J. Infect. Dis. 175 (Suppl. 1).
12. Dittman S. Epidemic diphtheria in the newly independent states of the former USSR - situation and lessons learned. Biologicals. 25:1997;179-186.
13. Mäkelä, P.H, Eskola, J., Käyhty, H. and Takala, A.K. (1995) Vaccines against Haemophilus influenzae type b. In: Molecular and Clinical Aspects of Bacterial Vaccine Development (Ala'Aldeen, D.A.A. and Hormaeche, C.E., Eds.), pp. 41-91. John Wiley and Sons.
14. Mosman T.R., Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today. 17:1996;138-146.
15. Fenyö, E.M. (1993) Viral pathogenesis and heterogeneity. In: Frontiers of Infectious Diseases. Focus on HIV (Levy, J.A., Neu, H.C. and Weiss, R., Eds.), pp 27-43. Churchill Livingstone Special Projects, London.
16. Behring E., Kitasato S. Ueber das Zustandenkommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren. Dtsch. Med. Wochenschr. 16:1890;1113-1114.
17. Koch, R. (1881) Zur Untersuchungen von Pathogenen Organismen. Mitteilungen aus dem Kaiserlichen Gesundheitsamt, pp. 1-48.
18. Woodruff A.M., Goodpasture E.W. The susceptibility of the chorio-allantonic membrane of chick embryos to infection with the fowl-pox virus. Am. J. Pathog. 7:1931;209-222.
19. Enders J.F., Weller T.H., Robbins F.C. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science. 109:1949;85-87.
20. McAleer W.J., Buynak E.B., Maigetter R.Z., Wampler D.E., Mller W.J., Hilleman M.R. Human hepatitis B vaccine from recombinant yeast. Nature. 307:1984;178.
21. Germanier R., Furer E. Immunity in experimental salmonellosis. II. Bias for the avirulence and protective capacity of gal E mutants of Salmonella typhimurium. Infect. Immun. 4:(6):1971;663-673.
22. Germanier R., Furer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J. Infect. Dis. 131:(5):1975;553-558.
23. Robbe-Saule V., Coynault C., Norel F. The live oral typhoid vaccine Ty21a is a rpoS mutant and is susceptible to various environmental stresses. FEMS Microbiol. Lett. 126:1995;171-176.
24. Taylor D.N., Sanchez J.L., Castro J.M., Lebron C., Parrado C.M., Johnson D.E., Tacket C.O., Losonsky G.A., Wasserman S.S., Levine M.M., Cryz S.J. Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama. Infect. Immun. 67:(4):1999;2030-2034.
25. Poliomyelitis prevention in the United States: Introduction of sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory committee on Immunization Practices (ACIP) MMWR Morb. Mortal Wkly rep 46, pp. 1-25.
26. Casadevall A., Scharff M.D. Serum therapy revisited: Animal models of infection and development of passive antibody therapy. Antimicrob. Agents Chemother. 38:1994;1695-1702.
27. Chudwin D.S. Prophylaxis and treatment of pneumococcal bacteremia by immune globulin intravenous in a mouse model. Clin. Immunol. Immunopathol. 50:1989;62-71.
28. Gold R., Artenstein M.S. Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull. World Health Org. 45:1971;279.
29. Wahdan M.H., Rizk F., El-Akkad A.M., El Ghoroury A.A., Hablas R., Girgis N.I., Boctar W., Sippel J.E., Gotschlich E.C., Triau R., Sanborn W.R., Ovjetanovic B. A controlled field trial of a serogroup A meningococcal polysaccharide vaccine. Bull. World Health Org. 48:1973;667.
30. Sanborn W.R., Bencic Z., Ovjetanovic B., Gotschloch E.C., Pollock T.M., Sippel J.E. Trial of a serogroup A meningococcus polysaccharide vaccine in Nigeria. Progr. Immunobiol. Stand. 5:1972;497.
31. Wyle F.A., Artnstein M.S., Brandt B.L., Tramont E.C., Kasper D.L., Altieri P.L., Berman S.L., Lowenthal J.P. Immunologic response of man to group B meningococcal polysaccharide vaccines. J. Infect. Dis. 126:1972;514-522.
32. Goldschneider I., Lepow M.L., Gotschlich E.C. Immunogenicity of the group a and group C meningococcal polysaccharides in children. J. Infect. Dis. 125:1971;509-519.
33. Finne J., Leinonen M., Mäkelä P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 13:(8346):1983;355-357.
34. Finne J., Mäkelä P.H. Cleavage of the polysialosyl units of brain glycoproteins by a bacteriophage endosialidase. Involvement of a long oligosaccharide segment in molecular interactions of polysialic acid. J. Biol. Chem. 260:(2):1985;1265-1270.
35. - B cell lineage. Cell. Immunol. 143:1992;66.
36. Käyhty H., Eskola J., Peltola H. Immunogenicity in infants of a vaccine composed of Haemophilus influenzae type b capsular polysaccharide mixed with DPT or conjugated to diphtheria toxoid. J. Infect. Dis. 155:1987;100-106.
37. Eskola J., Anttila M. Pneumococcal conjugate vaccines. Pediatr. Infect. Dis. J. 18:1999;543-551.
38. Black, S., Shinefield, H., Ray, P. et al. (1998) Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37 000 infants and children: results of the Northern California Kaiser Permanente efficacy trial (Abstract LB-9). In: 38th Interscience Conference of Antimicrobial Agents and Chemotherapy. San Diego, CA.
39. Relyveld E.H. Preparation and use of calcium phosphate adsorbed vaccines. Dev. Biol. Stand. 65:1986;131-136.
40. Loutan L., Bovier P., Althaus B., Gluck R. Inactivated virosome hepatitis a vaccine. Lancet. 343:1994;322-324.
41. Audebert F.M., Lise L.D. Adjuvants: Current status, clinical perspectives and future prospects. Immunol. Today. 14:1993;281-284.
42. Schirmbeck R., Melber K., Kuhrober A., et al. Immunization with soluble hepatitis B virus specific surface protein elicits murine H-2 class-I restricted cytotoxic T lymphocyte in vivo. J. Immunol. 152:1994;1110-1119.
43. Mowat A.M. The regulation of the immune responses to dietary antigens. Immunol. Today. 8:1987;93-98.
44. Holmgren J., Lycke N., Czerkinsky C. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine. 11:1993;1179-1184.
45. Schodel F. Prospects for oral vaccination using recombinant bacteria expressing viral epitopes. Adv. Virus Res. 41:1992;409-446.
46. Chatfield S.N., Roberts M., Dougan G., et al. The development of oral vaccines against parasitic diseases utilizing live attenuated Salmonella. Parasitology. 110:1995;S17-S24.
47. Tang D., DeVit M., Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature. 356:1992;152-154.
48. Donnelly J.J., Ulmer J.B., Shiver J.W., Liu M.A. DNA vaccines. Annu. Rev. Immunol. 15:1997;617-648.
49. Klinman D.M., Yi A.K., Beaucage S.L., Conover J., Krieg A.M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12 and interferon gamma. Proc. Natl. Acad. Sci. USA. 93:1996;2879-2883.
50. Moss B. Vaccinia virus: a tool for research and vaccine development. Science. 252:1991;1662-1667.
51. Brown A., Hormaeche C.E., DeMarco de Hormaeche R., et al. an attenuated aroA Salmonella typhimurium vaccine elicits humoral and cellular immunity to cloned β-galactosidase in mice. J. Infect. Dis. 155:1987;86-92.
52. Stover C.K., de la Cruz V.F., Fuerst T.R., et al. New use of BCG for recombinant vaccines. Nature. 351:1991;456-460.
53. Mason H.S., Lam D.M.K., Arntzen C.J. Expression of hepatitis B surface antigen in transgenic plants. Proc. Natl. Acad. Sci. USA. 89:1992;11745-11749.
54. Haq T.A., Mason H.S., Clements J.D., Arntzen C.J. Production of an orally immunogenic bacterial protein in transgenic plants: proof of concept of edible vaccines. Science. 268:1995;714-716.
55. Chang T.M.S. Biodegradable semipermeable microcapsules containing enzymes, hormones, vaccines and other biologicals. J. Bioeng. 1:1976;25-32.
56. O'Hagan D.T., Jeffrey H., Davis S.S. The preparation and characterization of poly (lactide-co-glycolide) microparticles. III. Microparticle/polymer degradation rates and the in vitro release of a model protein. Int. J. Pharm. 103:1994;37-43.
57. Morris W., Steinhoff M.C., Russell P.K. Potential of polymer microencapsulation technology for vaccine innovation. Vaccine. 12:1994;5-11.
58. Trollfors B., Taranger J., Lagergård T., et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N. Engl. J. Med. 333:1995;1045-1050.
59. Greco D., Salmaso S., Mastrantonio P., et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N. Engl. J. Med. 334:1996;341-348.
60. Gustafsson L., Hallander H.O., Olin P., et al. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334:1996;349-355.
61. Klugman K.P., Gilbertson I.T., Koorndorf H.J., et al. Vaccination advisory committee. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet. ii:1987;1165-1169.
62. Murphy B.R. Use of live attenuated cold-adapted influenza A reassortant virus vaccines in infants, children, young adults, and elderly adults. Infect. Dis. Clin. Pract. 2:1993;174-181.
63. Cunningham M.W., Antone S.M., Gulizia J.M., et al. Alpha-helical coiled-coil molecules: a role in autoimmunity against the heart. Clin. Immunol. Immunopathol. 68:1993;118-123.
64. Hsieh C.C., Tzonou A., Zavitsanos X., et al. Age at first establishment of chronic hepatitis B virus infection and hepatocellular carcinoma risk: A birth order study. Am. J. Epidemiol. 136:1992;1115-1121.
65. Yamada T., Ahnen D., Alpers D.H., et al. Helicobacter pylori in peptic ulcer disease. JAMA. 272:1994;65-69.
66. IARC (1994) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 61, pp. 177-240. World Health Organization, Lyon.
67. Hoffman K.J., Cook J.C., Joyce J.G., et al. Sequence determination of human papillomavirus type 6A and assembly of virus-like particles in Saccharomyces cerevisiae. Virology. 209:1995;506-518.
68. Cann P.L., Coursaget P., Iochmann S., Touze A. Self-assembly of human papillomavirus type 16 capsids by the expression of the L1 protein in insect cells. FEMS Microbiol. Lett. 117:1994;269-274.
69. Lin Y.L., Borenstein L.A., Selvakumar R., et al. Effective vaccination against papilloma development by immunisation with L1 and L2 structural protein of cottontail rabbit papillomavirus. Virology. 187:1992;612-619.
70. Hyöty H., Hiltunen M., Lönnrot M. Enterovirus infections and insulin dependent diabetes mellitus - evidence for causality. Clin. Diagn. Virol. 9:1998;77-84.
71. Mäkelä P.H. Is cardiovascular disease preventable by vaccination? Finn. Med. Soc. Duodecim Ann. Med. 31:1999;61-65.
72. Boon T., Certottini J., van den Eynde B., et al. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:1994;337-365.
73. Sanda M.G., Restifo N.-P., Walsh J.C., et al. Molecular characterization of defective antigen processing in human prostate cancer. J. Natl. Cancer Inst. 87:1995;280-285.
74. Garrido F., Cabrera T., Concha A., et al. Natural history of HLA expression during tumor development. Immunol. Today. 14:1993;491-499.
75. Dranoff D., Mulligan R.C. Gene transfer as cancer therapy. Adv. Immunol. 58:1995;417-455.
76. Pardoll D.M. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13:1995;399-415.
77. Tanaka K., Gorelik E., Watanabe M., et al. Rejection of B16 melanoma induced by expression of a transfected major histocompatibility complex class I gene. Mol. Cell Biol. 8:1988;1857-1861.
78. Ostrand-Rosenberg S., Thakur A., Clements V. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J. Immunol. 144:1990;4068-4071.